This new GLP-1 play is on a tear. UBS sees nearly a 50% gain from here
- Posted on May 12, 2026
- By CNBC
- 0 Views
- 1 min read
This new GLP-1 play is on a tear. UBS sees nearly a 50% gain from here
MBX Biosciences has rallied more than 230% over the past year, but there's room for still more upside from current levels, according to UBS.
